Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 7, 2015, 43 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $107.54 to $3,085,320.00.

Highlighted Stocks Traded by Insiders:

Covanta (CVA) - FREE Research Report

Orlando Anthony J, who is Director at Covanta, sold 140,000 shares at $22.04 on April 7, 2015. Following this transaction, the Director owned 144,242 shares meaning that the stake was reduced by 49.25% with the 140,000-share transaction.

The shares most recently traded at $21.95, down $0.09, or 0.4% since the insider transaction. Historical insider transactions for Covanta go as follows:

  • 4-Week # shares sold: 41,206
  • 12-Week # shares sold: 41,206
  • 24-Week # shares sold: 65,892

The average volume for Covanta has been 839,800 shares per day over the past 30 days. Covanta has a market cap of $2.9 billion and is part of the industrial goods sector and materials & construction industry. Shares are down 0.27% year-to-date as of the close of trading on Tuesday.

Covanta Holding Corporation provides waste and energy services to municipal entities primarily worldwide. It owns and operates infrastructure for the conversion of waste to energy, as well as engages in other waste disposal and renewable energy production businesses. The stock currently has a dividend yield of 4.54%. Currently, there are 5 analysts who rate Covanta a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVA - FREE

TheStreet Quant Ratings

rates Covanta as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and poor profit margins. Get the full

Covanta Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Itron (ITRI) - FREE Research Report

Glanville Thomas S, who is Director at Itron, sold 1,000 shares at $37.00 on April 7, 2015. Following this transaction, the Director owned 20,497 shares meaning that the stake was reduced by 4.65% with the 1,000-share transaction.

The shares most recently traded at $36.27, down $0.73, or 2.01% since the insider transaction. Historical insider transactions for Itron go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 4,560

The average volume for Itron has been 281,800 shares per day over the past 30 days. Itron has a market cap of $1.4 billion and is part of the technology sector and electronics industry. Shares are down 13.97% year-to-date as of the close of trading on Tuesday.

Itron, Inc. provides metering solutions to electricity, gas, and water utility markets worldwide. The company operates through three segments: Electricity, Gas, and Water. Currently, there is 1 analyst who rates Itron a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITRI - FREE

TheStreet Quant Ratings

rates Itron as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including poor profit margins and weak operating cash flow. Get the full

Itron Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amsurg (AMSG) - FREE Research Report

Holden Christopher A, who is President and CEO at Amsurg, sold 3,000 shares at $63.36 on April 7, 2015. Following this transaction, the President and CEO owned 297,496 shares meaning that the stake was reduced by 1% with the 3,000-share transaction.

The shares most recently traded at $62.61, down $0.75, or 1.2% since the insider transaction. Historical insider transactions for Amsurg go as follows:

  • 4-Week # shares sold: 12,098
  • 12-Week # shares sold: 21,097
  • 24-Week # shares sold: 24,097

The average volume for Amsurg has been 447,600 shares per day over the past 30 days. Amsurg has a market cap of $3.1 billion and is part of the health care sector and health services industry. Shares are up 14.11% year-to-date as of the close of trading on Tuesday.

AmSurg Corp., through its subsidiaries, provides ambulatory and physician services in the United States. The company operates through two divisions, Ambulatory Services and Physician Services. The company has a P/E ratio of 49.4. Currently, there are 8 analysts who rate Amsurg a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMSG - FREE

TheStreet Quant Ratings

rates Amsurg as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Amsurg Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null